Integrated MALDI-TOF MS, Antimicrobial Susceptibility Testing, and Real-Time Quantitative PCR for Characterization of Foodborne Pathogens and Antimicrobial Resistance in Ready-to-Eat Foods in Libya www.frontiersin.org Nov. 10, 2026, 11:37 p.m.
This study addresses critical public health threats posed by foodborne bacterial contamination and antimicrobial resistance in ready-to-eat foods across Libya's Al-Jabal Al-Akhdar region. Recognizing that conventional culture-based identification and susceptibility testing require up to 72 hours, researchers developed an integrated diagnostic workflow combining matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), phenotypic antimicrobial susceptibility testing, and real-time quantitative polymerase chain reaction (qPCR). Analysis of 400 RTE food samples collected throughout 2023 revealed bacterial growth in 37.5%, identifying 150 isolates including Staphylococcus aureus, Escherichia coli, Salmonella species, and Acinetobacter baumannii. MALDI-TOF MS achieved 96.7% accurate species-level identification, while phenotypic testing demonstrated multidrug resistance in 63.3% of isolates, with A. baumannii showing the highest prevalence at 87.0%. qPCR successfully identified key resistance genes with 82–88% genotype–phenotype concordance. This integrated approach reduced diagnostic time to approximately 24 hours, providing a practical framework for rapid surveillance of foodborne pathogens and antimicrobial resistance, directly supporting One Health initiatives and evidence-based food safety interventions.
Beyond Species Identification: Clinical Implications of Candida auris Clade Differentiation www.annlabmed.org Nov. 10, 2026, 11:37 p.m.
The World Health Organization designated Candida auris as a critical-priority fungal pathogen in 2022, prompting enhanced surveillance globally. In Korea, C. auris infection became a notifiable healthcare-associated disease effective March 29, 2026, with a new national surveillance framework established. Research by Kwon et al. characterized 339 C. auris isolates from 32 Korean hospitals over nearly three decades, revealing two epidemiologically distinct populations: the historically dominant East Asian clade II and the recently emerging clade I. Clade II isolates predominantly originated from ear specimens with sporadic occurrence, while clade I emerged in 2018 and increasingly associates with candidemia and hospital clusters, with two or more fungemia cases identified in eleven hospitals during 2022–2024. This epidemiological shift indicates Korea is transitioning from endemic clade II prevalence to an outbreak-prone environment where clade I poses heightened healthcare transmission risk. The clade distinction carries significant clinical implications beyond surveillance, affecting antifungal treatment strategies, as echinocandins remain recommended for initial therapy in most adult C. auris infections.
CRISPR-Based CANDI Platform Detects 15 NTM Species in 3.5 Hours clpmag.com Nov. 10, 2026, 11:36 p.m.
Researchers at the University of North Carolina at Chapel Hill and Tulane University have developed CANDI (CRISPR-assisted nanodroplet differential identification), a microfluidic diagnostic platform that rapidly identifies 15 nontuberculous mycobacteria (NTM) species directly from clinical specimens. Published in Science Translational Medicine, the assay achieves over 97% sensitivity and reduces turnaround time from weeks to hours—a significant advancement for clinical management. Since NTM species vary substantially in pathogenicity and treatment requirements, accurate species-level identification is critical for guiding appropriate antimicrobial therapy. The research team, led by Melissa B. Miller and Qingyun Liu, integrated population genomics, clinical microbiology, and CRISPR engineering, analyzing over 100,000 mycobacterial genomes to identify diagnostic targets that remain conserved within species while remaining distinct from other mycobacteria. This approach ensures diagnostic reliability across circulating bacterial strains encountered in clinical practice. The team secured a five-year R01 grant to support further clinical validation and assay expansion, positioning CANDI as a transformative tool for expediting NTM diagnosis and enabling clinicians to make more informed treatment decisions earlier in patient care.
Who pays for the wrong antibiotic? biotia.io Nov. 10, 2026, 11:36 p.m.
US patients frequently receive antibiotics ineffective against their actual pathogens, a problem termed discordant therapy that costs the healthcare system $2.2–4.6 billion annually. Approximately one in five patients with bloodstream infections receive initially ineffective drugs, associated with 46% higher mortality. While clinicians often prescribe empirically due to resource constraints and diagnostic limitations, the core barrier to deploying advanced diagnostics lies in economic misalignment rather than technology. Current diagnostics like conventional culture are inexpensive and widely available but miss anaerobic bacteria, fungi, and fastidious pathogens. Newer diagnostics, including AI-powered tools, offer net cost savings and improved outcomes by enabling targeted therapy, yet hospital budgeting silos prevent adoption—diagnostic costs fall to clinical labs while benefits accrue to pharmacies, wards, and insurers. Medicare and Medicaid programs shift excess costs to hospitals under fixed-payment models, while private insurance and outpatients bear dual burdens. Resolving this misalignment through cross-departmental coordination is essential to unlocking clinical and economic benefits of novel microbial diagnostics.
Des capteurs ultra-sensibles pour prévenir les maladies cardio-vasculaires fondation-lehn.fr Nov. 4, 2026, 12:32 a.m.
Les maladies cardio-vasculaires sont la première cause de mortalité dans le monde, des pathologies évitables lorsqu’elles sont décelées précocement. Le laboratoire de Paolo Samorì a développé une nouvelle génération de capteurs ultra-sensibles, pouvant notamment servir à collecter des données de santé. Ce type de dispositif permet d’alerter dès les premiers signes imperceptibles du développement d’une maladie cardio-vasculaire. Ce capteur nouvelle génération, couplé à la puissance d’analyse de l’Intelligence Artificelle, constitue un outil de prévention et de diagnostic prometteur.
Candida auris in the Middle East and North Africa www.mdpi.com Nov. 3, 2026, 1:36 p.m.
This article examines the epidemiology and characteristics of Candida auris, an emerging multidrug-resistant fungal pathogen, across the Middle East and North Africa. The research systematically reviews reported cases throughout the Gulf Region, including Saudi Arabia, Qatar, the United Arab Emirates, Kuwait, Oman, and Bahrain, as well as the Eastern Mediterranean Region and North African countries such as Egypt, Algeria, and Sudan. The study analyzes case distribution patterns across these geographic areas and compares pre-COVID and post-COVID emergence trends, revealing significant temporal shifts in disease prevalence. Notably, the research identifies predominant clade distributions specific to different regions, providing crucial insight into the pathogen's genetic diversity and geographic spread. Additionally, the analysis addresses antifungal resistance profiles, a critical concern given Candida auris's notorious resistance to multiple treatment options. This comprehensive regional assessment matters significantly for public health planning and infection control strategies, as Candida auris poses substantial clinical challenges in healthcare settings throughout the Middle East and North Africa, particularly in resource-constrained environments where surveillance and containment remain difficult.
From empirical to targeted therapy: A comprehensive review of clinical microbiological diagnostics for urinary tract infections icurology.org Nov. 3, 2026, 1:36 p.m.
Urinary tract infections represent a significant global health burden, affecting millions annually with rising antimicrobial resistance complicating treatment outcomes. This comprehensive review examines the clinical microbiological diagnostic workflow essential for accurate UTI management and targeted therapy. The article outlines the complete diagnostic pathway, beginning with specimen collection and traditional Gram staining, progressing through quantitative urine culture to advanced identification techniques including matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), biochemical assays, and multilocus sequence typing. The review also addresses antimicrobial susceptibility testing methods ranging from broth microdilution to automated systems and diffusion tests, alongside emerging molecular diagnostics such as multiplex polymerase chain reaction and next-generation sequencing for rapid resistance detection. The integration of conventional phenotypic testing with modern molecular diagnostics enables timely transition from empirical to targeted antimicrobial therapy, supporting antimicrobial stewardship initiatives and reducing unnecessary broad-spectrum antibiotic exposure. This systematic diagnostic approach proves increasingly critical as multidrug-resistant pathogens proliferate, ultimately advancing precision medicine implementation in UTI management while enhancing clinical outcomes.
Molecular Point-of-Care Testing for Infectious Diseases and Antimicrobial Resistance: Integrated Biosensing Technologies, Evidence Maturity, and Clinical and One Health Translation www.frontiersin.org Nov. 3, 2026, 1:35 p.m.
Molecular point-of-care testing (POCT) offers promise for rapid infectious-disease diagnosis to guide isolation, referral, and treatment decisions. This critical review examines POCT as an integrated biosensing system, integrating CRISPR-Cas recognition, isothermal amplification, microfluidic sample handling, nanomaterial-assisted preparation, and smartphone readout with considerations for contamination control, matrix tolerance, multiplexing, calibration, and reagent stability. The authors propose a five-domain framework evaluating mechanistic feasibility, analytical characterization, clinical accuracy, usability and operations, and clinical utility and implementation, applied to respiratory infections, sexually transmitted infections, and antimicrobial-resistance testing. While clinically evaluated cartridge systems demonstrate stronger diagnostic evidence than emerging prototypes, randomized trials show rapid pathogen identification does not necessarily reduce antibiotic prescribing, highlighting the distinction between genotypic resistance detection and phenotypic susceptibility testing. The One Health framework examines transferable engineering constraints in foodborne-pathogen detection, water surveillance, and antimicrobial-exposure monitoring. Key implementation priorities include internal process controls, transparent invalid-result reporting, prospective real-world evaluation, reproducible manufacturing, affordability, secure connectivity, and explicit linkage between test results and appropriate clinical actions.
Clinical Candida Testing www.thermofisher.com Nov. 3, 2026, 1:35 p.m.
Candida auris represents a significant global public health threat requiring rapid and accurate diagnostic identification and antifungal susceptibility testing. Recent comprehensive reviews and clinical studies address the critical diagnostic challenges posed by this emerging pathogenic yeast. Multiple identification methodologies have been evaluated, including MALDI-ToF mass spectrometry, which provides reliable species profiling capabilities. The Simplexa C. auris Direct assay demonstrates multicenter performance validation for detecting colonization through bilateral axilla and groin swabs, supporting efficient screening protocols. Current antifungal susceptibility testing against amphotericin B, echinocandins, and flucytosine now follows newly established European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints, enabling standardized interpretation of minimum inhibitory concentrations. These diagnostic advances are essential for clinical laboratories implementing effective surveillance and treatment strategies. As Candida auris continues spreading globally with documented antifungal resistance patterns, robust identification and susceptibility testing frameworks enable healthcare systems to promptly detect infections, guide therapeutic decisions, and implement appropriate infection control measures to mitigate transmission risks and improve patient outcomes.
Reframing decentralized diagnostics with a programmable www.nature.com Nov. 3, 2026, 1:34 p.m.
Researchers have developed a programmable multi-dimensional microfluidic system that significantly advances decentralized diagnostics, as reported in Nature Communications. This innovative platform, created by a team of scientists including Tao Xu, Ying Zhang, and colleagues, reimagines how diagnostic testing can be conducted outside traditional laboratory settings. The microfluidic technology enables simultaneous multi-parameter analysis from minimal sample volumes, enhancing diagnostic accuracy and speed while reducing costs associated with centralized testing facilities. By leveraging programmable microfluidics—a technique that allows precise control of fluid behavior at microscale—the system can perform diverse diagnostic functions on a single integrated device. This breakthrough is particularly significant for point-of-care testing applications, enabling healthcare providers to deliver rapid, accurate diagnostics in remote or resource-limited settings. The approach addresses critical gaps in accessible healthcare by democratizing diagnostic capabilities, potentially transforming disease detection and management protocols in global health contexts.
Clinical and Economic Outcomes Associated with Rapid Antimicrobial Susceptibility Reporting and Dual-Card Testing in ICU Bloodstream Infections www.dovepress.com Oct. 24, 2026, 7:42 a.m.
Researchers from Yancheng Clinical College evaluated a comprehensive antimicrobial stewardship intervention targeting ICU patients with bloodstream infections. Between March 2022 and June 2023, the laboratory implemented an optimized workflow incorporating satellite blood culture incubation in the emergency department, upgraded culture bottles, rapid MALDI-TOF MS identification, automated rapid antimicrobial susceptibility testing (AST) reporting, and dual AST cards for Gram-negative bacteria. Comparing 153 post-optimization patients to 107 pre-optimization controls, results demonstrated that rapid AST reporting was 19.6 hours faster than conventional reporting. Total antibiotic duration decreased by 1.5 days, with significant reductions in broad-spectrum antibiotic usage, including meropenem and tigecycline. Hospital length of stay was reduced by five days. These findings underscore the substantial clinical and economic benefits of expedited diagnostic workflows in managing bloodstream infections, enabling faster pathogen identification and appropriate targeted antimicrobial therapy while reducing unnecessary broad-spectrum antibiotic exposure and healthcare costs.
Rapid Point-of-Care (POC) vs. Molecular PCR Diagnostics: How Modern CLIA-Certified Laboratories Deliver Accurate Answers in Minutes urnextlab.com Oct. 24, 2026, 7:42 a.m.
UR Next Lab and Services Solutions, LLC addresses the clinical challenge of balancing diagnostic speed with accuracy in infectious disease testing. The company offers two complementary approaches: FDA-cleared, CLIA-waived Point-of-Care rapid diagnostics delivering results in ten to fifteen minutes, and Molecular RT-PCR/NAAT amplification panels for definitive diagnosis. Point-of-Care antigen tests employ monoclonal antibodies on nitrocellulose membranes or fluorescence cartridges to detect viral proteins or bacterial antigens from nasal or throat swabs, providing quick clinical guidance when symptoms are evident. Conversely, Reverse Transcription Polymerase Chain Reaction and Nucleic Acid Amplification Testing represent the gold standard for molecular diagnosis, directly amplifying pathogenic genetic material through thermal cycling. This approach exponentially multiplies viral RNA or DNA sequences—potentially generating over one billion copies from a single molecule within thirty-five to forty cycles—enabling detection of as few as one hundred to five hundred viral copies per milliliter. This superior sensitivity allows molecular testing to identify infections days before rapid tests become positive and maintains sensitivity throughout recovery, making it invaluable when early-stage symptoms are ambiguous or rapid tests yield false negatives despite clinical presentation.
Molecular diagnostics shifts from single tests to lab infrastructure - Medical Buyer medicalbuyer.co.in Oct. 24, 2026, 7:41 a.m.
Molecular diagnostics is undergoing a fundamental transformation from a specialized niche to core laboratory infrastructure, marking a shift from crisis-driven pandemic demand to sustainable, technology-anchored growth. The Indian molecular diagnostics market, valued at approximately ₹9,400 crore (USD 1 billion) in 2025, exemplifies this evolution. Characterized as reagent-heavy and PCR-anchored, it remains substantially import-dependent while expanding into genomics and oncology applications across smaller cities. The segment is transitioning from double-digit pandemic-era growth rates to projected compound annual growth of six to eight percent through the decade, reflecting a stabilization around infectious disease, oncology, and genetic testing rather than single-pathogen spikes. This structural shift is reshaping procurement economics, technology choices, and industry consolidation patterns. For diagnostic chains, hospital laboratories, and equipment suppliers, the strategic imperative has shifted from capacity expansion to optimizing workflows, capital allocation, and integrated reagent-driven infrastructure. The market's emphasis on reagents and consumables over analyzers underscores this transition, positioning reagent supply chains and workflow integration as competitive differentiators in the evolving molecular diagnostics landscape.
Economic Barriers to Antimicrobial Susceptibility Testing as a Structural Contributor to Antimicrobial Resistance in Low- and Middle-Income Countries: A Narrative Review www.dovepress.com Oct. 24, 2026, 7:41 a.m.
Bacterial antimicrobial resistance caused an estimated 1.27 million deaths in 2019, yet antimicrobial susceptibility testing (AST)—essential for guiding targeted therapy and stewardship—remains inaccessible in low-resource settings. Researchers from Hormuud University in Somalia conducted a narrative review of literature published between 2019 and 2026, searching PubMed, Scopus, and Google Scholar for studies addressing economic barriers to AST implementation in low- and middle-income countries. The analysis identified three interconnected levels of economic obstruction: patient-level barriers including out-of-pocket costs and transportation; laboratory-level constraints such as infrastructure deficits, reagent shortages, and insufficient workforce; and health-system-level underinvestment coupled with donor dependency. These barriers perpetuate broad-spectrum empirical prescribing, amplifying selection pressure and driving emergence of resistant organisms including methicillin-resistant Staphylococcus aureus, extended-spectrum β-lactamase-producing Enterobacterales, and carbapenem-resistant pathogens. Consequences extend beyond treatment failure to catastrophic household expenditures and threats to universal health coverage. The authors recommend subsidized diagnostics, insurance coverage for microbiology services, tiered laboratory strengthening, and integrated diagnostic and antimicrobial stewardship programs as essential responses to scale AST accessibility and combat resistance.
New Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVD finance.yahoo.com Oct. 24, 2026, 7:40 a.m.
AmplexDiagnostics and Scope Biosciences have announced eazySNP, an innovative molecular diagnostic technology that combines LAMP and CRISPR methodologies to enable rapid and highly specific detection of genetic variants. The collaboration represents a significant advancement in molecular SNP diagnostics. The first CE-IVD certified product, eazySNP C. auris FKS1 S639, targets Candidozyma auris, a multidrug-resistant yeast pathogen of major clinical concern. This assay rapidly identifies echinocandin-resistance mutations in the FKS1 gene—critical for treatment planning since echinocandins are the first-line therapy for C. auris infections. Performed directly from yeast colonies using the eazyMini platform, results are delivered within 45 minutes, providing laboratories with the first rapid molecular solution for detecting this clinically important resistance marker. For Scope Biosciences, this launch marks a strategic expansion from plant health diagnostics into human molecular diagnostics, demonstrating the commercial viability of their CRISPR technology platform.
Le jour où le château de cartes de Theranos a commencé à s’effondrer cafetech.substack.com Oct. 23, 2026, 1:59 p.m.
“La nouvelle Steve Jobs”. En septembre 2015, le magazine Inc. consacre sa couverture et un portrait dithyrambique à Elizabeth Holmes. Personne ne le sait encore, mais ce sont les derniers instants de gloire pour la fondatrice de Theranos, devenue alors, à 31 ans, la plus jeune milliardaire non héritière au monde. Le 16 octobre, le château de cartes qu’elle a bâti pendant onze ans commence à s’effondrer, à la suite de la publication d’une enquête dévastatrice du Wall Street Journal. Malgré les dénégations, ces révélations emporteront tout sur leur passage, précipitant la chute de l’entrepreneuse et la conduisant jusqu’en prison.
Why broader access to advanced diagnostics is key to health equity in Asia www.weforum.org Oct. 17, 2026, 7:35 a.m.
Advanced diagnostics determine over 70% of clinical decisions yet receive only 2% of global healthcare spending, creating a critical gap in health equity—particularly in Asia-Pacific. The region faces disproportionate disease burdens, accounting for 62.6% of global liver disease deaths, 60% of tuberculosis cases, and nearly half of global breast cancer diagnoses, compounded by rapid population ageing projected to increase significantly by 2050. This diagnostic underinvestment has serious consequences: missed or imprecise diagnoses cannot always be corrected later, even with advanced therapies, affecting critical applications like immunosuppressive drug dosing post-transplant. Technological innovations, particularly automated mass spectrometry, are transforming access to precision diagnostics in routine clinical settings across Asia-Pacific. By enabling high-specificity molecular detection without requiring specialized laboratory facilities, these scalable technologies make precision care accessible where it's needed most. Expanding diagnostic capabilities in the region is essential to manage rising chronic disease burdens and address the current undervaluation of diagnostics by both medical professionals and policymakers globally.
Tracking Candida auris www.cdc.gov Oct. 17, 2026, 7:35 a.m.
The United States recorded 6,304 new clinical cases of Candida auris in 2024, continuing an upward trajectory since the fungus's first U.S. detection in 2016, though the rate of increase has recently slowed. C. auris cases are identified through clinical samples from invasive sites like blood or cerebrospinal fluid, or non-invasive sites such as urine and wounds, with screening cases detected through colonization swabs. While transmission persists in certain geographic areas and has expanded into new regions, recommended infection prevention and control practices have successfully contained outbreaks in some locations when implemented early. The CDC, collaborating with state and local health departments, diagnostic laboratories, and healthcare facilities, tracks cases reported through standardized Council of State and Territorial Epidemiologists definitions and provides support via its Antimicrobial Resistance Lab Network. Proactive case detection, patient screening, and rigorous adherence to infection control protocols remain critical for preventing healthcare facility outbreaks and limiting this emerging threat's spread.
Rapid identification and antimicrobial susceptibility testing of journals.plos.org Oct. 17, 2026, 7:34 a.m.
Researchers have developed a rapid diagnostic approach for identifying pathogenic microorganisms directly from positive blood cultures and simultaneously determining their antimicrobial susceptibility profiles. Published in PLOS One by Xu and colleagues, this study addresses a critical clinical challenge in sepsis management, where timely identification of bloodstream pathogens and their resistance patterns is essential for appropriate antibiotic selection. Traditional methods require lengthy culture periods, delaying treatment decisions and potentially compromising patient outcomes. The research presents an expedited testing methodology that significantly reduces the time-to-result for both pathogen identification and susceptibility testing from positive blood culture samples. By enabling faster diagnosis and resistance profiling, this approach allows clinicians to implement targeted antimicrobial therapy more rapidly, potentially improving treatment efficacy and reducing inappropriate antibiotic use. The innovation holds substantial value for intensive care settings and clinical microbiology laboratories, where rapid turnaround times directly impact patient prognosis in life-threatening bloodstream infections.
Point-of-Care CRISPR-Based Diagnostics: Split System Advances www.omnicuris.com Oct. 17, 2026, 7:33 a.m.
Point-of-care CRISPR-based diagnostics represent a transformative approach to molecular testing that combines laboratory precision with rapid, decentralized deployment. While traditional CRISPR platforms utilize intact guide RNA and single Cas effector proteins, they frequently suffer from background signal leakage, off-target activation, and complex sample preparation. Bioengineers have developed split molecular systems that address these limitations by dividing essential CRISPR components into inactive fragments that remain non-functional until a target sequence appears in the sample. Upon target hybridization, these fragments spontaneously assemble into an active Cas complex that initiates collateral cleavage of reporter molecules. This conditional mechanism dramatically suppresses baseline noise while enabling extraordinary diagnostic fidelity. The split crRNA architecture divides the guide RNA into multiple inactive fragments that cannot independently activate Cas endonucleases. When a specific complementary target sequence is introduced, rapid hybridization triggers reassembly of a complete, catalytically functional guide RNA. This dual-recognition system suppresses spurious enzymatic activation and prevents accidental off-target cleavage from mismatched sequences. By fine-tuning thermodynamic hybridization properties of each fragment, assay designers achieve single-base discrimination, enabling reliable differentiation of viral variants and drug-resistant bacterial strains. This split system approach establishes a dependable foundation for high-precision molecular detection in primary care settings without requiring expensive laboratory infrastructure.